OncoMatch/Clinical Trials/NCT06563505
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Is NCT06563505 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Mosunetuzumab and Zanubrutinib for lymphoma.
Treatment: Mosunetuzumab · Zanubrutinib — To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CD20 monoclonal antibody
Have received at least 1 prior treatment including CD20 monoclonal antibody
Cannot have received: chemotherapeutic agent or other anti-lymphoma agent (investigational or otherwise)
Treatment with any chemotherapeutic agent, or treatment with any other anti-lymphoma agent (investigational or otherwise) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to first investigational agent administration.
Lab requirements
Blood counts
Blood counts below if without lymphoma cause for cytopenia: Hemoglobin ≥ 8 g/dL; Platelets ≥ 75 x 10^9/L; ANC ≥ 1.0x10^9/L. If cytopenia due to lymphoma: Hemoglobin ≥ 6 g/dL (no transfusion within 7 days prior to treatment); Platelets ≥ 50 x 10^9/L; ANC ≥ 0.5x10^9/L
Kidney function
Creatinine clearance ≥ 40 ml/min calculated by modified Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 institutional ULN, unless consistent with Gilbert's (ratio between total and direct bilirubin > 5); AST (SGOT) and ALT (SGPT) ≤ 3 x institutional ULN; Alkaline phosphatase < 2.5 ULN
Patients must have adequate organ and marrow function as defined below: * Total bilirubin ≤ 1.5 institutional ULN, unless consistent with Gilbert's (ratio between total and direct bilirubin > 5) * AST (SGOT) and ALT (SGPT) ≤ 3 x institutional ULN * Alkaline phosphatase < 2.5 ULN * Creatinine clearance ≥ 40 ml/min calculated by modified Cockcroft-Gault formula * Blood counts below if without lymphoma cause for cytopenia * Hemoglobin ≥ 8 g/dL * Platelets ≥ 75 x 10^9/L * Absolute neutrophil count (ANC) ≥ 1.0x10^9/L * Blood counts below if cytopenia are due to lymphoma (such as bone marrow involvement or splenomegaly) * Hemoglobin ≥ 6 g/dL (no transfusion within 7 days prior to treatment) * Platelets ≥ 50 x 10^9/L * Absolute neutrophil count (ANC) ≥ 0.5x10^9/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06563505 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapeutic agent or other anti-lymphoma agent (investigational or otherwise) disqualifies patients from enrollment.
What disease stage is eligible?
Stage II or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify